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Abstract
Background: Early identification of children and adolescents with type 1 diabetes at high risk for development
of complications is important, as early intervention may prevent further deterioration. Here we investigate the
applicability of assessing skin advanced glycation end products (sAGEs) by skin autofluorescence (SAF) as a
potential surrogate risk marker.
Methods: This study included a cross-sectional analysis of SAF in 77 patients with type 1 diabetes mellitus and
118 healthy controls across age categories (11–12, 13–14, 15–16, and 17–19 years old). In patients, the impact of
current and historical glycated hemoglobin (HbA1c) values, age, and duration of diabetes on SAF was studied in a
retrospective cohort study and analyzed with multivariable analyses.
Results: SAF was significantly and similarly higher in patients when compared with controls across all age
categories (P ≤0.009). For patients, age, duration of diabetes, and current and historical HbA1c were associated with
SAF in univariate analysis. Multivariate analysis showed no association between HbA1c and SAF. A subgroup of
patients with a HbA1c-within-target (≤7.5 %/59 mmol/mol) were observed to have high SAF.
Conclusion: Children and adolescents with type 1 diabetes show higher SAF than controls. The presumed
correlation of high HbA1c with high SAF does not exist in all patients. Thus, use of this non-invasive measure
may provide a surrogate marker for diabetic complications, additional to HbA1c.
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Background
Reactive oxygen species and non-enzymatic reactions
between sugars and amino groups of proteins (‘Maillard
reaction’) are involved in the formation of advanced gly-
cation end products (AGEs) [1]. AGEs cause oxidative
stress-related tissue damage [1], which plays an important
role in microvascular and macrovascular complications in
diabetes [2].
As skin collagen has a half-life of 10–15 years [3], skin
AGEs (sAGEs) represent long-term glycemia. Accumula-
tion of sAGEs can be assessed easily and non-invasively
by measuring skin autofluorescence (SAF) [4] or skin
intrinsic fluorescence (SIF) [5, 6]. sAGEs have been pro-
posed as a surrogate measure for risk assessment add-
itional to HbA1c in patients with diabetes [7]. In adults,
increased levels of sAGEs were found in patients who
developed complications [7–9]. As early intervention
may prevent damage later in the disease course of diabetes
[10], identification of young patients at high risk for mi-
cro- and macrovascular complications is of paramount
importance [11]. SAF/SIF may be an effective measure-
ment to identify this disadvantaged group. Previous stud-
ies assessed SAF/SIF in a rather heterogeneous group of
children and adolescents with type 1 diabetes [12, 13], but
some lacked a proper control group [14, 15]. Felipe et al.
[5] found SIFto be weakly associated with mean HbA1c of
the preceding period and with diabetes duration.
Here we investigate if SAF reflects glycemic control
expressed by HbA1c in a homogeneous study popula-
tion. SAF in Dutch Caucasian children and adolescents
with type 1 diabetes was compared with SAF in healthy
Caucasian controls. In patients, associations of SAF with
age, diabetes duration, gender, and current and historical
(past) HbA1c as a reflection of long-term glycemic
control were determined. We hypothesize that SAF will
be higher in patients compared with controls and that it
will associate with the variables age, historical HbA1c,
and diabetes duration.
Methods
Study design and population
The study design was a retrospective cohort study of pa-
tients with type 1 diabetes and healthy controls. Patients
aged 11–19 years with type 1 diabetes ≥3 months were
recruited between April 2010 and January 2013 while
visiting the outpatient clinic of Diabeter, a certified center
of reference for diabetes care in Rotterdam, Netherlands.
Diabeter provides comprehensive and advanced manage-
ment for children and adolescents with type 1 diabetes.
Patients were only included if they were Caucasian and if
measurements of SAF and HbA1c were performed on the
same day. Patients with inadequately controlled celiac
disease, hypothyroidism, and those using lipid-lowering
therapy were excluded.
The healthy control group was recruited from a second-
ary school in Rotterdam in October and November 2011.
Controls with missing data, non-Caucasian ethnicity, and
concomitant diseases other than attention deficit/hyper-
activity disorder were excluded. Study participants and
parents of minors provided signed informed consent. The
study was approved by the Medical Ethical Board of the
Erasmus Medical Center, Rotterdam, Netherlands, and
performed in accordance with the Declaration of Helsinki.
Anthropometric and laboratory data
In controls, information on gender, ethnic background,
and concomitant diseases was collected. Anthropometric
and laboratory data were not obtained for this group. In
patients, information on duration of diabetes, gender,
body mass index (BMI), blood pressure, current HbA1c,
and HbA1c values in the past (called ‘historical HbA1c’
from here on) was retrieved from electronic patient
charts. Information on BMI and blood pressure was in-
cluded if measurements were performed within a time
interval of 1 month around the SAF measurement. BMI
was converted to standard deviation scores (SDS): a high
BMI was defined as a BMI ≥+2 SDS. A normal BMI was
defined as a BMI <+2 SDS [16–18]. Systolic blood pres-
sure (SBP) and diastolic blood pressure (DBP) were con-
verted to percentiles [19]. HbA1c was measured at every
clinic visit by immunochemical assay (Vantage System,
Siemens Medical Solutions Diagnostics, Tarrytown, NY)
with intra- and inter-assay coefficients of variation of
<3.7 % and <4.3 %, respectively. Current HbA1c was de-
fined as the HbA1c measured on the same day as SAF.
Historical HbA1c was defined as the median intraper-
sonal HbA1c value of multiple HbA1c data included
from the first clinic visit onwards. Historical HbA1c was
only determined if the first HbA1c measurement was
done ≥3 months after the diagnosis of type 1 diabetes
and if ≥3 HbA1c measurements were done in the period
from the first measurement to the current HbA1c meas-
urement (current HbA1c measurement not included). A
current or historical HbA1c >7.5 %/59 mmol/mol was
defined as ‘HbA1c-above-target’ whereas an HbA1c of
≤7.5 %/59 mmol/mol was defined as (relatively) ‘Hba1c-
within-target’ [20].
SAF measurements
Patient SAF measurements were performed at Diabeter.
Measurements of controls were performed at their
school. The volar side of the forearm was measured with
the AGE Reader CU autofluorescence reader (Diagnoptics
BV, Groningen, Netherlands), making sure that the site of
measurement was clean. The autofluorescence reader
illuminates a skin surface of approximately 1 cm2 with an
excitation light source between 300 and 420 nm (peak ex-
citation ∼ 350 nm) [21]. Three independent measurements
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were performed in approximately 30 s: the arm was repo-
sitioned between measurements. The mean of the three
measurements was displayed by the SAF reader in arbi-
trary units. Previously, Sugisawa et al. [22] reported a coef-
ficient of diurnal variation of 3.7 % and a coefficient of
daily variance of 4.6 %.
Statistical methods
Due to the lack of prior data on SAF measurements in pa-
tients and controls as well as absence of data on the rela-
tionship between HbA1c and SAF in diabetes patients,
formal sample size could not be calculated at study onset.
Instead, our aim was to include at least 100 students and
at least 70 diabetics during the study period.
Normal distributions were expressed as mean with SD.
Continuous variables with skewed distributions were
expressed as median with interquartile range (IQR). Cat-
egorical variables were expressed as proportions and
percentages. Differences in continuous variables between
groups were tested with the Mann-Whitney U test. Dif-
ferences in categorical variables between groups were
tested by the chi-squared test or Fisher’s exact test.
Correlations were tested with Pearson’s rho in case of nor-
mal distribution and Spearman’s rho in case of skewed
distribution. Patients with type 1 diabetes and controls
were stratified into multiple age categories (11–12, 13–14,
15–16, and 17–19 years). For each age category, patients
were stratified according to HbA1c-above-target and
Hba1c-within-target. For both patients with HbA1c-
above-target and Hba1c-within-target, SAF was descrip-
tively compared with SAF of controls.
Univariate and multiple linear regression analyses were
performed. Univariate linear regression analyses were
used to assess the impact of the following covariables
on SAF: age; diabetes duration (≤4 years, 4 to <10 years,
and ≥10 years); gender; current HbA1c (current value, and
HbA1c-above-target/Hba1c-within-target); and historical
HbA1c (historical value, and HbA1c-above-target/Hba1c-
within-target). BMI was not included due to low variability
in BMI values. SBP and DBP were not included because
no associations with SAF were found. Multiple linear
regression analyses were performed using two models.
Model 1 assessed the impact of age and diabetes duration
on SAF. In model 2, current and historical HbA1c were




A total of 99 patients with type 1 diabetes and 141
controls were recruited, of whom 77 patients and 118
healthy controls were included (Fig. 1). Baseline charac-
teristics of patients and controls are presented in Table 1.
The median age of patients with type 1 diabetes was
higher than controls (P = 0.004). Females were signifi-
cantly overrepresented in the control group (P = 0.042).
Historical HbA1c was determined in 73 patients (median
26 HbA1c measurements; IQR 17–37; range 3–71) in a
period of 4.12 years (IQR 2.43–6.07 years; range 0.75–
13.88 years).
SAF measurements in controls and patients
Figure 2 shows SAF measurements per age category for
the controls, and for the patients with historical HbA1c-
above-target and Hba1c-within-target. Both the overall
SAF (patients: median [IQR] SAF 1.40 [1.23–1.54]; con-
trols: mean [SD] SAF 1.14 [0.14], P <0.001) and the me-
dian SAF in the different age categories were significantly
higher in patients when compared to controls (Fig. 2). In
the control group, median SAF increased from 1.10 [IQR
1.00–1.20] in the age category 11–12 years to 1.40 [IQR
1.10–1.40] in the age category 17–19 years. In the patient
group, the same pattern was seen: in the age category 11–
12 years, median SAF was 1.24 [IQR 1.19–1.40], and in
Fig. 1 Study profile. SAF skin autofluorescence
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the age category 17–19 years, median SAF was 1.53 [IQR
1.48–1.66] (Fig. 2).
Impact of HbA1c on SAF in patients
Within the patient group, median SAF of patients
with a current HbA1c-within-target (n = 13) was 1.32
[IQR 1.19–1.52] and of patients with a historical HbA1c-
above-target (n = 64) 1.40 [IQR 1.22–1.54](P = 0.654). In
the same group, median SAF of patients with a historical
HbA1c-within-target (n = 19) was 1.36 [IQR 1.23–1.50]
and of patients with a historical HbA1c-above-target
(n = 54) 1.41 [1.23–1.54](P = 0.580). There were also
no statistically significant differences in SAF between
the HbA1c-above-target and HbA1c-within-target patients
for the various age categories (Fig. 2).
Figure 3 shows the association between historical
HbA1c and SAF. The Spearman correlation coefficient
between historical HbA1c and SAF was 0.292 (P = 0.012).
Figure 3 also shows that 11 patients with a historical
HbA1c-within-target had an elevated SAF >1.28 (mean
SAF of controls + 1 SD), whereas 1 patient with a his-
torical HbA1c-above-target had a decreased SAF <1.00
(mean SAF of controls −1 SD).
Univariate linear regression analyses (Table 2) showed
a significant impact of age, diabetes duration, current
HbA1c, historical HbA1c, current HbA1c (HbA1c-
above-target/Hba1c-within-target), and historical HbA1c
(HbA1c-above-target/Hba1c-within-target) on SAF. We
found no significant impact of gender on SAF. Adjusted
R2 did not exceed 0.207.
For the multiple linear regression analyses (Table 2),
Model 1 showed a significant effect of ‘diabetes duration
≥10 years’ and age on SAF. In Model 2 the addition of the
current HbA1c (HbA1c-above-target/Hba1c-within-tar-
get) and historical HbA1c (HbA1c-above-target/Hba1c-
within-target) showed a significant impact of age and
Table 1 Baseline characteristics of patients with type 1 diabetes
and healthy controls
Patients: n = 77 Controls: n = 118
Age, years 15.3 (13.6–17.0) 14.4 (13.1–15.4)
Gender: female, n (%) 39 (50.6 %) 77 (65.3)
Diabetes duration, years (IQR) 6.6 (3.5–9.5) NA
Age at diabetes onset, years (IQR) 8.9 (5.7–11.4) NA
SBP (percentile) 78 (49–91)a NA
DBP (percentile) 37 (21–66)a
BMI, n (%) NA
≤ −2 SDS -
> −2 SDS and <0 SDS 16 (21.6)b
≥0 SDS and <+2 SDS 55 (74.3)b
≥ +2 SDS 3 (4.1)b




a n = 69
b n = 74
c n = 73
DBP diastolic blood pressure, IQR interquartile range, SBP systolic blood
pressure, SDS standard deviations score
Fig. 2 Age-specific median skin autofluorescence (SAF) in patients with a HbA1c-above-target (>7.5 %/59 mmol/mol) and a HbA1c-within-target
(≤7.5 %/59 mmol/mol), compared with controls. P-values: comparison of patients vs controls per age category by Mann-Whitney U test. Error bars:
interquartile range
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diabetes duration but not of current or historical HbA1c
on SAF. The adjusted R2 increased to 0.235.
Discussion
Consistent with previous studies [5, 14, 15], patients
with type 1 diabetes showed significantly higher SAF
than controls, both for the group as a whole and across
all age categories. It is important to note that this was
already apparent for the lowest age category (age 11–12
years). SAF appeared to increase faster in the elder ado-
lescents for both patients and controls and with diabetes
duration in patients. Differences in SAF between current
Fig. 3 Correlation between historical HbA1c and skin autofluorescence (SAF) in children and adolescents with type 1 diabetes. amean SAF of
controls + 1 SD. bmean SAF of controls -1SD. cHbA1c-within-target (≤7.5 %/59 mmol/mol) vs HbA1c-above-target (>7.5 %/59 mmol/mol)
Table 2 Univariate and multiple linear regression analyses (n = 77) to assess the impact of the following covariables on SAF: age;
diabetes duration; gender; current HbA1c (current value, and HbA1c-above-target/ HbA1c-within-target); and historical HbA1c
(historical value, and HbA1c-above-target/ HbA1c-within-target)
Beta coefficient 95 % CI P-value Adjusted R2
Univariate analysis
Age (years) 0.047 0.026, 0.067 <0.001 0.207
Duration of diabetes (years) 0.025 0.013, 0.038 <0.001 0.172
Sex (male/female) 0.047 −0.056, 0.150 0.366 −0.002
Current HbA1c (%) 0.056 0.019, 0.092 0.003 0.097
Historical HbA1c (%) (n = 73) 0.057 0.003, 0.111 0.040 0.045
Current HbA1c: HbA1c-above-target vs. Hba1c-within-target 0.034 −0.104, 0.172 0.628 −0.010
Historical HbA1c: HbA1c-above-target vs. Hba1c-within-target (n = 73) 0.028 −0.092, 0.147 0.645 −0.011
Multiple linear regression analysis
Model 1 (n = 77) 0.265
Age (years) 0.040 0.019, 0.061 <0.001
Diabetes duration 4 to <10 years vs. ≤ 4 years 0.065 −0.044, 0.172 0.239
Diabetes duration ≥10 years vs. ≤ 4 years 0.187 0.053, 0.320 0.007
Model 2 (n = 73) 0.235
Age (years) 0.043 0.022, 0.065 <0.001
Diabetes duration 4 to <10 years vs. ≤ 4 years 0.056 −0.064, 0.175 0.356
Diabetes duration ≥10 years vs. ≤ 4 years 0.179 0.030, 0.328 0.019
Current HbA1c: HbA1c-above-target vs. Hba1c-within-target 0.012 −0.138, 0.162 0.872
Historical HbA1c: HbA1c-above-target vs. Hba1c-within-target −0.048 −0.172, 0.077 0.446
HbA1c-above-target: > 7.5 %/59 mmol/mol; Hba1c-within-target HbA1c: ≤ 7.5 %/59 mmol/mol
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HbA1c-within-target and HbA1c-above-target patients
and between historical Hba1c-within-target and HbA1c-
above-target patients were small. In addition, SAF was
only weakly associated with diabetes duration and
HbA1c (both current and historical) in our homoge-
neous group of Dutch Caucasians, consistent with SIF
findings from Felipe et al. [5]. This association disappeared
when adjusting for diabetes duration and age. Interest-
ingly, a subgroup of patients with a Hba1c-within-target
had an elevated SAF. Previous studies showed conflicting
results on the association between historical HbA1c and
SAF [7, 22]. A strong correlation between historical
HbA1c and SAF would be expected, as SAF is believed to
be at least partly caused by hyperglycemia-induced super-
oxide and carbonyl damage, resulting in permanent
damage to long-lived proteins such as collagen [3, 23].
However, in this study, a strong association between his-
torical HbA1c and SAF could not be demonstrated. An
explanation may be that the period during which historical
HbA1c was determined was too short or that median
intra-individual HbA1c is an inadequate parameter to
express historical HbA1c. Alternatively, as sAGEs are con-
sidered to be formed by various pathways [7, 23, 24], the
influence of hyperglycemia on SAF may also be overesti-
mated. It is intriguing to see that some patients show an
elevated SAF despite having a HbA1c-within-target. This
may be explained by genetic factors influencing either the
level of glycation of HbA1c or by factors that influence
AGE formation such as polymorphisms of the AGE-
receptor (RAGE) gene [25] or the NAT2 acetylator [26].
Also, oxidative/carbonyl stress may play a role [24, 27],
which may be hypoglycemia-related [28]. An outstanding
question is if this heterogeneity in patients reflects
differences in risk for complications. If so, then SAF
measurement in this subgroup may provide informa-
tion on risk for complications independent of HbA1c.
However, one should bear in mind that Sun et al.
showed in the Medalist Joslin study group that cer-
tain types of plasma AGEs are associated with risk of
complications and others are protective [29]. In addition,
Conway et al. suggest that also resistance to AGEs may
play a role [30].
A strength of this study was that adjustment for skin
color was not necessary, as measured patients and con-
trols were from the same ethnic background (Caucasian).
Homogeneity of the patient population supports internal
validity. However, the results cannot be applied to non-
Caucasians and therefore generalizability is lower. Also,
we studied the age range 11–19 years in more detail when
compared with previous studies [5, 12, 31], showing
clearly that children and adolescents with type 1 diabetes
in the age category 11–12 years already have elevated
SAF. We took into account the use of skin care products,
as these can affect SAF readings [32]. One limitation of
our study as well as previous studies [5, 15] is that we
were unable to quantify measurement errors in terms of
coefficient of variation. To reduce measurement error as
much as possible, only one type of AGE-reader was used
and SAF measurements were performed in triplicate.
However, when measuring SAF is to be of use in routine
clinical practice, precision CV of these measurements will
have to be assessed to be able to distinguish measurement
error from clinically meaningful SAF measurements. SAF
readings may be confounded by a number of behavioral
factors such as dietary factors and fasting state [33]. Add-
itional factors such as smoking and exercise are implicated
in the accumulation of SAF [20, 28]. We could not adjust
for these factors. BMI may influence SAF, in particu-
lar in individuals with central obesity [34]. We did
not extend the BMI analyses as only four patients had a
BMI >+2 SDS.
Conclusion
In summary, children and adolescents with type 1 dia-
betes show higher SAF than controls. Age and duration
of diabetes are weakly associated with SAF. In the majority
of patients, SAF does not seem to provide information
additional to HbA1c. However, in a subgroup of patients
with HbA1c-within-target an elevated SAF was observed.
For this subgroup, measuring SAF may have added
value in identifying patients that are at high risk for
complications. Further longitudinal, prospective stud-
ies should provide insight into whether SAF measure-
ment in youngsters has predictive value for the
development of complications during the disease course
of type 1 diabetes and how this is related to glycemic
control.
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